1. Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, Liu Z, Nelson JD, Nichols JJ, Tsubota K, Stapleton F. TFOS DEWS II definition and classification report. Ocul Surf 2017;15:276-283.
2. Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, Knop E, Markoulli M, Ogawa Y, Perez V, Uchino Y, Yokoi N, Zoukhri D, Sullivan DA. TFOS DEWS II pathophysiology report. Ocul Surf 2017;15:438-510.
3. Baudouin C, Messmer EM, Aragona P, Geerling G, Akova YA, Benítez-del-Castillo J, Boboridis KG, Merayo-Lloves J, Rolando M, Labetoulle M. Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction. Br J Ophthalmol 2016;100:300-306.
4. Chhadva P, Goldhardt R, Galor A. Meibomian gland disease: the role of gland dysfunction in dry eye disease. Ophthalmology 2017;124:S20-S26.
5. Borchman D. The optimum temperature for the heat therapy for meibomian gland dysfunction. Ocul Surf 2019;02. 19. [Epub]. 10.1016/j.jtos.2019.02.005.
6. Jones L, Downie LE, Korb D, Benitez-Del-Castillo JM, Dana R, Deng SX, Dong PN, Geerling G, Hida RY, Liu Y, Seo KY, Tauber J, Wakamatsu TH, Xu J, Wolffsohn JS, Craig JP. TFOS DEWS II management and therapy report. Ocul Surf 2017;15:575-628.
7. Drug and Therapeutics Bulletin. The management of dry eye. BMJ 2016;353:i2333.
8. Pescosolido N, Parisi F, Buomprisco G, Librando A. New therapies in common ocular surface disorders. Clin Ter 2013;164:e405-e411.
9. Pan Q, Angelina A, Marrone M, Stark WJ, Akpek EK. Autologous serum eye drops for dry eye. Cochrane Database Syst Rev 2017;2:CD009327.
10. Ervin AM, Wojciechowski R, Schein O. Punctal occlusion for dry eye syndrome. Cochrane Database Syst Rev 2010;(9):CD006775.
11. Nam K, Kim HJ, Yoo A. Efficacy and safety of topical 3% diquafosol ophthalmic solution for the treatment of multifactorial dry eye disease: meta-analysis of randomized clinical trials. Ophthalmic Res 2019;01. 17. [Epub]. 10.1159/000492896.
12. Holland EJ, Darvish M, Nichol KK, Jones L, Karpecki PM. Efficacy of topical ophthalmic drugs in the treatment of dry eye disease: a systematic literature review. Ocul Surf 2019;03. 04. [Epub]. 10.1016/j.jtos.2019.02.012.
14. Zhao X, Xia S, Chen Y. Comparison of the efficacy between topical diquafosol and artificial tears in the treatment of dry eye following cataract surgery: a meta-analysis of randomized controlled trials. Medicine (Baltimore) 2017;96:e8174.
15. Burnstock G. The therapeutic potential of purinergic signalling. Biochem Pharmacol 2018;151:157-165.
16. Igarashi T, Fujita M, Yamada Y, Kobayashi M, Fujimoto C, Takahashi H, Igarashi T, Nakano Y, Suzuki H, Takahashi H. Improvements in signs and symptoms of dry eye after instillation of 2% rebamipide. J Nippon Med Sch 2015;82:229-236.
18. Qiao J, Yan X. Emerging treatment options for meibomian gland dysfunction. Clin Ophthalmol 2013;7:1797-1803.
20. Foulks GN, Borchman D, Yappert M, Kakar S. Topical azithromycin and oral doxycycline therapy of meibomian gland dysfunction: a comparative clinical and spectroscopic pilot study. Cornea 2013;32:44-53.
21. Dogru M, Nakamura M, Shimazaki J, Tsubota K. Changing trends in the treatment of dry-eye disease. Expert Opin Investig Drugs 2013;22:1581-1601.
24. Vora GK, Gupta PK. Intense pulsed light therapy for the treatment of evaporative dry eye disease. Curr Opin Ophthalmol 2015;26:314-318.